Besides the new cases, 15,858 recoveries were reported in the country in the same period, the Ministry said.

The total count includes 1,35,926 active cases and 1,05,89,230 recoveries.

The COVID-19 death toll has reached 1,55,447 with 87 people succumbed to the virus in the last 24 hours.

As many as 75,05,010 COVID-19 vaccines have been administered in the country so far.

A total of 20,40,23,840 samples have been tested for the coronavirus as of February 10. Of these, 6,99,185 samples were tested on Wednesday, the Indian Council of Medical Research (ICMR) informed.

The post India registers 9,309 new COVID-19 cases, 87 deaths appeared first on The Gulf Indians.

Moreover, with 117 deaths related to the novel coronavirus infection, total fatality in the country has surged to 1,53,587.

India currently has 1,77,266 active cases and 1,03,45,985 people have been recovered and discharged so far.

According to the Indian Council of Medical Research (ICMR), 19,30,62,694 samples have been tested for Covid-19 detection up to January 25 with 7,25,577 of them being tested on Monday.

The post India reports lowest daily spike in eight months appeared first on The Gulf Indians.

Dr V K Paul, a member(Health), NITI Aayog, said on Tuesday that Covishield of Serum Institute of India, and Covaxin are the two COVID-19 vaccines that have received Emergency Use Authorisation (EAU). He said that these vaccines are the safest vaccines and have been tested on thousands of people and side-effects are negligible.

The Union Health Ministry has said apart from Covishield and Covaxin, there are four more vaccines in the pipeline. Their manufacturers may soon apply for emergency use authorisation in India.

Union Health Secretary Rajesh Bhushan said Zydus Cadilla, Sputnik V, Biological E and Gennova are the COVID-19 vaccines that are in the pipeline and are currently in advanced clinical trials in Indian

About half a crore doses of Serum Institute of India (SII’s) Covishield vaccine were shipped out of Pune to cities across India on January 12, as the country launched its final phase of preparations for the mass inoculation drive against the novel coronavirus.

What one dose of Covid vaccines will cost in India?

Covishield: Rs 200 per dose (for first 100 million doses), Rs 1,000 per dose thereafter at private outlets
Covaxin: Rs 206 per dose
Pfizer-BioNTech: Rs 1,431 per dose
Moderna: Rs 2,348 to Rs 2,715 per dose
Sinopharm: less than Rs 5,650 per dose
Sinovac Biotech: Rs 1,027 per dose
Novavax: Rs 1,114 per dose
Gamaleya Centre: less than Rs 734 per dose
Johnson and Johnson: Rs 734 per dose

Meanwhile, India reported 15,968 new Covid-19 cases, 17,817 discharges and 202 deaths in last 24 hours, as per Union Health Ministry data. The total cases now stand at 1,04,95,147, active cases are 2,14,507 and overall recoveries is at 1,01,29,111. The total death toll is 1,51,529.

According to the Indian Council of Medical Research, a total of 18,34,89,114 samples tested for Covid-19 till 12th January, of which 8,36,227 samples were tested on January 12.

The post After Serum, Bharat Biotech dispatches first dose of Covaxin in India appeared first on The Gulf Indians.

With 336 new deaths, the toll mounted to 1,43,355 as of Monday, with total active cases at 3,52,586.

The health ministry said that more than 70 percent of the deaths occurred due to comorbodities.

The total discharged cases are at 93,88,159 with 30,695 new discharges in the last 24 hours.

The COVID-19 caseload of the country remained below 4 lakh for the eighth consecutive day on Monday. The national recovery rate is at 94.98 percent, while the case fatality rate stands at 1.45 percent.

India’s Covid-19 tally had crossed the 20-lakh mark on August 7, 30 lakh on August 23 and 40 lakh on September 5.
It went past 50 lakh on September 16, 60 lakh on September 28,
70 lakh on October 11, crossed 80 lakh on October 29 and surpassed 90 lakh on November 2.

A total of 15,45,66,990 samples tested for COVID-19 up to December 13. Of these, 8,55,157 samples were tested yesterday said Indian Council of Medical Research.

On December 13, Delhi recorded 1,984 fresh Covid-19 cases which pushed the infection tally to 6.07 lakh, while the death toll crossed the 10,000 mark with 33 new fatalities.

These fresh cases came after conducting 72,335 tests including 35,611 RT-PCR tests, according to the latest bulletin issued by the Delhi health department.

With over 98.57 lakh total coronavirus cases, India’s active caseload continues to decline and is currently below 3.6 lakh, the union ministry of health said.

The post Daily COVID-19 cases in India dip below 30,000 for third time in Dec appeared first on The Gulf Indians.

With 520 new deaths reported in the last 24 hours, the toll mounts to 1,29,188.

The total number of active cases stand at 4,80,719 after a decrease of 3,828 in the last 24 hours.

Total discharged cases stand at 81,63,572 with 47,992 new discharges in the last 24 hours.

#CoronaVirusUpdates:

📍Total #COVID19 Cases in India (as on November 14, 2020)

➡️93.05% Cured/Discharged/Migrated (8,16,35,72)
➡️5.48% Active cases (4,80,719)
➡️1.47% Deaths (1,29,188)

Total COVID-19 confirmed cases = Cured/Discharged/Migrated+Active cases+Deaths pic.twitter.com/KXjPLi1Tmd

— #IndiaFightsCorona (@COVIDNewsByMIB) November 14, 2020

The Ministry of Health revealed that, the recovery rate in India is at 93.05 percent while the fatality rate is at 1.47 percent. The active cases comprise of 5.48 percent of the total cases as of Saturday.

Maharashtra has reported 85,583 active cases, 16,05,064 recoveries and 45,682 deaths due to the disease so far while Karnataka recorded 29,489 active cases, 8,14,949 recoveries and 11,474 deaths so far.

The national capital reported 43,116 active cases and 7,332 deaths while 4,16,580 people recovered from the infection till now.

According to the Indian Council of Medical Research (ICMR), a total of 12,40,31,230 samples have been tested for COVID-19.

COVID-19 Testing Update. For more details visit: https://t.co/dI1pqvXAsZ @MoHFW_INDIA @DeptHealthRes #ICMRFIGHTSCOVID19 #IndiaFightsCOVID19 #CoronaUpdatesInIndia #COVID19 pic.twitter.com/hrWG5TkchP

— ICMR (@ICMRDELHI) November 14, 2020

The post India reports 44,684 new coronavirus cases appeared first on The Gulf Indians.

The total number of active cases now stands at 5,05,265 after a decrease of 4,408 in the last 24 hours.

Total recovered cases are at 79,59,406 with 42,033 new discharges in the last 24 hours.

India’s COVID-19 active cases have fallen below six percent of the total cases.

In a tweet, the Health Ministry said, “ Demonstrating a landmark achievement, India’s active cases have fallen below 6% of the total cases. The recovered cases have leaped past 92% of the cumulative cases.”

In another tweet, it said, “Caliberated and effective strategy of the Center focused on high levels of testing for early identification combined with timely tracing, isolation and hospitalisation of the severe cases have resulted in a manageable number of active cases and continuously rising number of recoveries.”

Delhi has overtaken Maharashtra and Kerala by reporting 7,745 infections in a span of 24 hours to become the largest contributor to the single-day infections.

According to the Indian Council of Medical Research (ICMR), a total of 11,96,15,857 samples have been tested for coronavirus till November 9. Of these 10,43,665 samples were tested on November 9.

The post India’s COVID-19 active cases falls below six percent of the total cases appeared first on The Gulf Indians.

According to the updated health ministry data, 557 coronavirus patients succumbed to the coronavirus in the past 24 hours, taking the death toll in the country due to the infection to over 1.25 lakh.

India currently has 5,16,632 active coronavirus cases after a decrease of 4,141 in the last 24 hours. So far, 78,19,887 people have been discharged. On Friday, 53,920 coronavirus patients were discharged.

According to the Indian Council of Medical Research (ICMR), India has so far tested 11,65,42,304 samples to detect coronavirus. Of these, 11,13,209 samples were tested on November 6.

India’s single-day coronavirus recoveries exceeded daily new infections successively for the past five weeks, while active cases are on a sustained decline.

There is a continuous decline in average daily new cases for the last five weeks. The ministry had said on Friday that 80 per cent of the new recovered cases are observed to be concentrated in 10 states and union territories.

The post India registers 50,357 new coronavirus cases appeared first on The Gulf Indians.

The pharma company’s immediate focus is to conduct the Phase 3 trials successfully across sites in the country.

The company’s vaccine candidate, Covaxin, has been developed in collaboration with the Indian Council of Medical Research-National Institute of Virology using inactivated Sars-Cov-2. The virus was isolated in an ICMR lab.

The price of the vaccine is yet to be determined, as the company is still looking at the cost of product development.

Bharat Biotech received approval from the Drugs Controller General of India to conduct Phase 3 clinical trial to establish the efficacy of the vaccine candidate. The company has begun site preparatory exercises for Phase 3, recruitment and dosage will begin in November.

The trial is conducted in nealy 30 sites around 14 states. About 2,000 subjects are enrolled per hospital and will provide tow doses each of the vaccine and placebo recipients.

The pharma company is looking to supply for both government and private markets. It is also in its preliminary discussions with other countries for probable supply.

Nearly Rs 350-400 crore is invested for the development of vaccines and the new manufacturing facilities, which include investments for conducting the Phase 3 clinical trials, in the next three months.

The post Bharat Biotech to launch Covaxin in mid-2021 appeared first on The Gulf Indians.

In a single day, 579 coronavirus positive patients succumbed to the Covid-19 infection, according to the Health Ministry data.

India stood second behind the United States in terms of total cases of coronavirus. The country tops in terms of the number of recovered cases and third in terms of fatalities globally behind the US and Brazil.

India’s total Covid-19 tally has climbed to 75,50,273. India has also seen a dip of 11,256 in its active cases since Sunday. As of Monday morning, there are 7,72,055 active cases of coronavirus in India. So far, 66,63,608 have recovered from the infection and 1,14,610 people have died from the coronavirus.

Maharashtra, Andhra Pradesh and Karnataka have reported the highest number of cases. However, infections are rising rapidly in states like Tamil Nadu, Uttar Pradesh and West Bengal. Yet, India’s recovery rate continues to rise and now stands at 88 percent.

The Indian Council of Medical Research (ICMR) has said that 9,50,83,976 samples were tested for COVID-19 in the country till yesterday (October 18). Of these, 8,59,786 were tested on Sunday (October 18).

The post Coroanvirus caseload over 75lakh in India appeared first on The Gulf Indians.

The number of new fatalities also saw a drop for the ninth consecutive day. India recorded 816 deaths due to the infection in the last 24 hours.

Nearly 84 per cent of these fatlities are reported from 10 states, with Maharashtra having reported maximum number (308) of these deaths. The fatality count now stands at 1,09,150.
The number of active cases fell further to 8,61,853, while 61,49,535 patients have cured of the disease, according to health ministry.

It took 110 days for the Covid-19 cases in the country to reach one lakh while it had taken 59 days more to go past the 10-lakh mark.

The Covid-19 case fatality rate (CFR) stands at 1.54 per cent, the health ministry had said on October 11.

According to Indian Council of Medical Research (ICMR), a cumulative total of 8,68,77,242 samples have been tested till October 10 with 10,78,544 samples being tested on October 10.

The post COVID-19: India’s daily count falls, total tally crosses 71 lakh. appeared first on The Gulf Indians.

There has been a reduction in the number of active cases, indicating the daily recoveries exceeded the number of infections. India’s total number of active cases has come down to 9,34,427 on Monday.

The country has been posting high level of daily recoveries for the past few weeks and 76,737 recoveries were registered in the last 24 hours. Now 5,586,703 people have been cured so far taking the national recovery rate to 84.34%.

The new recoveries have exceeded the fresh cases of the coronavirus disease in the recent days. India has the highest number of recoveries in the world at the moment. The number of deaths in India has also witnessed a marginal dip in the past couple of days.

Maharashtra, which has the highest number of active cases in the country, has also contributed the highest number to the newly-recovered cases followed by Karnataka and Andhra Pradesh.

The government also said that 10 states and Union Territories account for 77. 11% of the active cases in the country. Out of the total new cases, 78% were concentrated in 10 states and Union territories with Maharashtra contributing more than 14,000 to the new cases. Karnataka and Kerala reported 9,886 and 7834 new cases, respectively, according to government data.

India has exceeded the World Health Organisation (WHO) recommendations on daily testing per million by nearly six times, according to the health ministry. The Indian Council of Medical Research (ICMR) has said that nearly 8 crore samples have been tested for Covid-19 in the country up to October 4. ICMR said a total of 7,99,82,394 samples have been tested so far. Of these, 9,89,860 samples were tested yesterday.

The post COVID-19: India’s recovery rate improves further appeared first on The Gulf Indians.

On September 27, Air India Express announced that health authorities in Dubai will no longer accept RT-PCR Covid-19 test results from four laboratories in India.

“The RT-PCR negative Covid-19 reports from four Indian Council of Medical Research (ICMR)-approved laboratories – Suryam Lab in Jaipur, Microhealth Labs in Kerala, Dr P Bhasin Pathlabs Ltd. in Delhi, and the Noble Diagnostic Centre in Delhi – will not be accepted anymore,” the airline said in its travel blog.

Passengers to Dubai are advised to obtain pre-travel RT-PCR reports from Pure Health-approved laboratories, it said.

On September 28, over 200 Indian passengers heading to Dubai were barred from boarding their flights because their Covid-19 test results were deemed invalid, airport authorities said. They were carrying RT-PCR reports from the blacklisted laboratories.

At Kannur International Airport in Kerala, 117 passengers were denied permission to board an Air India Express flight to Dubai, according to an airport official. At Kozhikode International Airport, some 100 passengers were held back. Only 66 adult passengers and one child were allowed to board the flight leaving at 12.30 pm. Those stranded were given free replacement tickets.
A GoAir flight to Dubai took special permission from the UAE authorities to ensure smooth operations for the day, the official said.

Neeraj Agarwal, consul for Press, Information, and Culture at the Indian Consulate in Dubai, said that passengers wishing to fly from India to Dubai can bring test report from other ICMR-approved facilities, except the four labs barred by Dubai authorities.

Kerala’s Micro Health Laboratories, one of the blacklisted labs, said the problem was created by 2,600 fake test results issued by another lab forging its letterhead and stamps.

Micro Health, which has 27 labs across the world and franchise labs in Kerala, had partnered with the UAE’s official testing facility, Pure Health, in July.

The lab has now referred the matter to the police and has also launched a QR code system to check the authenticity of the test results.

The post Dubai blacklists four Indian labs for Covid tests appeared first on The Gulf Indians.

All Air India Express flights to and from Dubai will operate as per original schedule with effect from September 19, the airline announced on Twitter and Facebook on September 19. This announcement followed a one day suspension ordered by the Dubai Civil Aviation Authority for flouting COVID-19 travel regulations.

Regarding the suspension notice from DCAA, Air India Express said: “The notice has been issued on account of erroneous acceptance of two Covid-19 positive passengers by the airline’s ground handling agents, one at Delhi and another at Jaipur.” It added: “As per information gathered, passengers who were seated in close proximity to the Covid-19 positive passenger on each flight have undergone tests and quarantined as determined by the Dubai Health Authority.”

On September 18, the DCAA had ordered a 15-day suspension of the airline’s Dubai operations and its Dubai flights had to be rescheduled to Sharjah. The rescheduled flights were to Kozhikode (Calicut), Thiruvananthapuram, Delhi, Mumbai and Kannur. Barring one or two, most of the passengers flew on the rescheduled flights both ways, an airline official said.

The airline pointed out that before receiving the notice, it submitted a letter to the DCAA expressing the airline’s sincere apologies and detailing the various actions taken by it in association with the ground handling agents concerned to safeguard against repeat of such incidents.

“Air India Express has advised the handling agents to implement a three-tier checking mechanism to avoid any such lapse in the future,” it said.
The DCAA has asked Air India to pay for all the expenditures incurred by the respective authorities regarding medical/ quarantine of any passenger on the flights that carried the two COVID-positive travellers.

The UAE has made it mandatory for all incoming passengers to procure a Covid-19 negative test result. Passengers travelling from India can get the test done from a Pure Health or an Indian Council of Medical Research (ICMR) approved laboratory.

India has an air bubble agreement with UAE that is valid till October 31.

The post Air India Express resumes Dubai flights after brief suspension appeared first on The Gulf Indians.

While the Government and Industry were trying their best to make available a safe and effective vaccine for COVID-19 at the earliest, it was difficult to comment on the exact timelines in view of various complex pathways involved in vaccine development, according to Minister of State (Health and Family Welfare) Ashwini Kumar Choubey.

In a written reply in the Rajya Sabha on September 15, Mr. Choubey said, that the Government has constituted a high-level National Expert Group on vaccine administration for COVID-19 which is chaired by Member, Niti Aayog and co-chaired by Secretary, Ministry of Health & Family Welfare. Other representatives are: Secretary, Ministry of External Affairs, Secretary, Department of Biotechnology, Secretary, Department of Health Research, Director General of Health Services, Ministry of Health & Family Welfare, Director, All India Institute of Medical Sciences, Head ECD, Indian Council of Medical Research, Director Jawaharlal Institute of Postgraduate Medical Education and Research (Member NTAGI) and Representatives from States & D/o Expenditure. The committee is addressing issues related to vaccine delivery, selection of suitable vaccines, procurement, prioritization of groups, logistics: Cold chain requirements, finance and National/International equity.

Central Drugs Standard Control Organisation (CDSCO) has granted test license permission for manufacture of COVID-19 Vaccine for pre-clinical test, examination and analysis to the following manufacturers in India.

M/s Serum Institute of India Pvt., Ltd., Pune, M/s Cadila Healthcare Ltd., Ahmadabad, M/s Bharat Biotech International Ltd., Hyderabad, Biological E Ltd., Hyderabad, M/s Reliance Life Sciences Pvt Ltd., Mumbai, M/s Aurbindo Pharma Limited, Hyderabad and M/s Gennova Biopharmaceuticals Limited, Pune are the companies involved.

The Indian Council of Medical Research (ICMR), an autonomous organisation under the Department of Health Research, has informed that the following companies are conducting clinical trials for COVID-19 vaccines in India:

(i) An inactivated whole virion candidate vaccine (BBV152) for SARS-CoV-2 has been developed by Bharat Biotech International Ltd (BBIL) using the virus isolate (NIV-2020-770) provided by ICMR-National Institute of Virology (NIV), Pune. Characterization of the vaccine candidate has been undertaken at ICMR-NIV followed by safety and tolerability studies in small animals like rats, mice and rabbits. Status of clinical trials is as follows:

Phase I clinical trials along with parallel studies in large animals have been completed. The trial has revealed excellent safety of the candidate vaccine. Immunogenicity testing is in progress.

Phase II clinical trials were ongoing.

(ii) A DNA vaccine (ZyCov-D) has been developed by Cadila Healthcare Ltd. Pre- clincial toxicity studies were conducted in small animals: mice, rats, rabbits and guinea pigs. The vaccine has been found to be safe and immunogenic. Cadila has partnered with ICMR for conduct of parallel pre-clinical studies in large animals. Status of clinical trials is as follows:

Phase I clinical trials have been completed. The trial has revealed excellent safety of the candidate vaccine. Immunogenicity testing is in progress.

Phase II clinical trials were ongoing.

(iii) Serum Institute of India (SII) and ICMR have partnered for clinical development of two global vaccine candidates:

ChAdOx1-S, which is a non- replicating viral vector vaccine developed by University of Oxford/AstraZeneca. This vaccine is undergoing phase III clinical trials in Brazil. Phase II/III bridging studies have been initiated by ICMR at 14 clinical trial sites. ICMR-National Institute for Research in Tuberculosis (NIRT), Chennai is the lead institution.

ICMR and SII have also partnered for clinical development of a glycoprotein subunit nanoparticle adjuvanted vaccine developed by Novavax from USA. The trial will be initiated in second half of October after the vaccine is manufactured by SII. The trial is led by ICMR-National AIDS Research Institute (NARI), Pune.

As per details provided by Department of Biotechnology (DBT)/Department of Science and Technology(DST), more than 30 vaccine candidates have been supported which are in different stages of development.

The ICMR has allocated Rs.25.00 crore for various studies and other research activities pertaining to vaccine development.

The Science and Engineering Research Board (SERB), a statutory body under the Department of Science and Technology, has supported three projects under COVID-19 on vaccine research under Intensified Research in High Priority Areas (IRHPA) The sanctioned expenditure is Rs.22,27,579/- and the committed expenditure is Rs.3,20,78,161/-.

The Department of Biotechnology is also supporting eight proposals by Industry and academia for candidate vaccine development and associated research resources at a total cost of Rs. 75 crore, the statement said.

The post Can’t comment on COVID-19 vaccine release timelines, says Minister appeared first on The Gulf Indians.

The total cases of coronavirus infections mounted to 29,05,823, while the death toll climbed to?54,849 with 983 new fatalities being reported in a span of 24 hours, the data updated at 8 am showed

Case fatality rate has declined to 1.89 per cent while the recovery rate has risen to 74.30 per cent. There are 6,92,028 active cases of coronavirus infection in the country which is 23.82 per cent of the total caseload, the data stated

India’s COVID-19 tally had crossed the 20-lakh mark on August 7.?

According to the Indian Council of Medical Research (ICMR), a cumulative total of 3,34,67,237 samples have been tested up to August 20 with 8,05,985 samples being tested on August 20.

The post India’s coronavirus tally zooms past 29 lakh mark appeared first on The Gulf Indians.

Around 803 COVID-19 deaths were reported in the last 24 hours making the total death toll to 38,938.

According to the Union Health Ministry data, there are now 5,86,298 active cases across the country, while 12,30,509 patients have been discharged.

Almost five months after India recorded first COVID-19 case, the country crossed the one million mark of active cases on July 17.

Maharashtra continues to be the worst-affected state as it has a total of 1,47,324 active cases and 15,842 deaths. A total of 4,50,196 coronavirus cases have been recorded in the state up to August 2, according to Union Ministry of Health.

Tamil Nadu witnessed 5,609 new COVID-19 cases and 109 death on August 3, taking total cases to 2,63,222 including 2,02,283 discharges and 4,241 deaths.

The total cases in Delhi have risen to 1,38,482 including 1,24,254 recovered/discharged/migrated cases and 4,021 deaths, according to the Ministry of Health.

Along with the number of covid-19 cases, the number of tests too have gone up in the country. On August 3, India recorded its highest single- day testing by conducting over 6.6lakh tests to diagnose Covid-19.

The total number of tests carried out in India has also crossed the two-crore mark, according to the Indian Council of Medical Research (ICMR).

The covid-19 recovery rate stands at 65.77 percent in the country, while the fatality rate is at 2.11 percent.

India continues to improve the Case Fatality Rate(CFR) and it is one of the lowest Covid-19 fatalities recorded globally.

The post COVID-19: Single day spike of 52,050 fresh cases in India appeared first on The Gulf Indians.

The study also indicated that a large number of infected persons remain asymptomatic. The survey was conducted from 27th of June 2020 to 10th July 2020 and was conducted following a rigorous multi-stage sampling study design. It is one of the largest sero-prevalence studies conducted in the country using the ELISA testing.

For all the 11 districts of Delhi, survey teams were formed. Blood samples were collected from selected individuals after taking written informed consent and then their sera were tested for IgG antibodies and infection using COVID KAVACH ELISA approved by Indian Council for Medical Research (ICMR).

As many as 21,387 samples were collected as per lab standards and were tested. The tests helped in identification of presence of antibodies in the general population. This test performed is not a diagnostic test but only provides information about past infection due to SARSCoV-2 in individuals who test positive.

Antibody testing repeatedly done over time i.e. sero-surveillance, generates important evidence for assessing the spread of the pandemic from time to time.

The final analysis of the result was:

1. Nearly six months into the epidemic, only 23.48% of the people are affected in Delhi, which has several pockets of dense population. This can be attributed to the proactive efforts taken by the Government to prevent the spread of infection including prompt lockdown, effective containment and surveillance measures, including contact tracing and tracking, as well as citizen’s compliance to covid appropriate behaviours.

2. However, a significant proportion of the population is still vulnerable. Therefore, the containment measures need to continue with the same rigour. Non-pharmacological interventions such as physical distancing, use of face mask/cover, hand hygiene, cough etiquette and avoidance of crowded places etc. must be followed strictly.

The post Nearly 23 percent residents in Delhi have coronavirus antibodies appeared first on The Gulf Indians.